1/3🚀JHEP Twittorial🚀 ☘️A step forward for targeting Hippo pathway in CCA 🔓👉bit.ly/3DV8ljg CCAs 👉⬆️activity of oncogenic LCK (Src family tyrosine kinase)/YAP (Yes-associated protein) dependent Hippo path Hippo💊👉challenge Rory L. Smoot & cols👇👇 #livertwitter

Dr. Tomlinson presenting our work with aptamer targeted RNA therapeutics for #cholangiocarcinoma #AACR2023 Cholangiocarcinoma Foundation Mayo Clinic Department of Surgery Mayo Clinic Comprehensive Cancer Center

A talented research technician from my group, Danielle Carlson, presenting our data on targeting hsf1 activity in #cholangiocarcinoma patient-derived xenografts. #aacr2023 Cholangiocarcinoma Foundation Mayo Clinic Department of Surgery Mayo Clinic Comprehensive Cancer Center

New The Lancet - Kelley et al - Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) thelancet.com/journals/lance… #gitwitter #onctwitter

Another great contribution from the Guggenheim 17 family. #Senescence in cholangiocytes via ETS1. #PSC ⁦Nicholas F LaRusso, M.D.⁩ ⁦Christy Trussoni⁩ ⁦Mayo Clinic Gastroenterology & Hepatology⁩ gastrojournal.org/article/S0016-…

Post doctoral fellow Dr. Shohei Takaichi presenting his work unraveling resistance mechanisms in #cholangiocarcinoma at #AACR2023. Cholangiocarcinoma Foundation Mayo Clinic Department of Surgery Mayo Clinic Comprehensive Cancer Center

Happy to see friends and mentees teaming up to produce a nice piece.

It’s Cholangiocarcinoma Awareness month. Our growing #CCA discovery science team celebrated #WorldCCADAY. 5 teams under one #CCA umbrella all with one mission: to improve outcomes for our CCA patients. #greenforCCA Cholangiocarcinoma Foundation

Excited to share some our latest research. doi.org/10.1093/pnasne…

The inaugural Basic science track day at the Cholangiocarcinoma Foundation Annual Conference is off to a great start. Fantastic first session with remarkable speakers and robust discussion focused on nanoparticles, adoptive cell therapy, innovative models, and CCA multiomics. Daniela Sia Gregory Lesinski

Fantastic presentation by Dr. Jennifer Tomlinson, a talented surgery resident, at the Cholangiocarcinoma Foundation Meeting highlighting her work on targeting TEADs.

In this paper in press, we demonstrate a dual role of TRAIL-TRAIL-R in #CCA 👉🏼 Noncanonical TRAIL signaling augments MDSC abundance 👉🏼 Canonical TRAIL signaling promotes CCA cell apoptosis but is less potent 👉🏼MDSC are resistant to TRAIL-induced apoptosis bit.ly/449CnL9